Pfizer, BioNTech post early-stage data for COVID-flu combo shot

CROCOTHERY

• Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced Thursday plans to run a pivotal Phase 3 trial for their mRNA-based combination vaccine candidates for influenza and COVID-19 after a Phase 1/2 study generated positive data.
• In the trial for healthy adults aged